SAN FRANCISCO — Six years ago at the J.P. Morgan Healthcare Conference, Intercept Pharmaceuticals (ICPT) sent investors (and journalists) scrambling to Google the definition of NASH after the surprising and positive results from a mid-stage clinical trial sent the biotech’s stock price soaring.
It’s been a long and bumpy road since January 2014, but Intercept’s NASH drug, called obeticholic acid, or OCA, is finally on the cusp of a highly anticipated Food and Drug Administration approval and commercial launch later this year.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
